velphoro
vifor fresenius medical care renal pharma france - sucroferric oxyhydroxide - hyperphosphatemia; renal dialysis - farmaci per il trattamento di iperkaliemia ed iperfosfatemia - velphoro è indicato per il controllo dei livelli sierici di fosforo nei pazienti adulti affetti da malattia renale cronica (ckd) in emodialisi (hd) o dialisi peritoneale (pd). velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with ckd stages 4-5 (defined by a glomerular filtration rate.
velphoro compresse masticabili
vifor fresenius medical care renal pharma ltd. - ferro da stiro - compresse masticabili - portato oxyhydroxidum/sintetico/amyla 2500.00 mg corrisp. ferro da stiro a 500,00 mg, sono (waldbeere), neohesperidini dihydrochalconum, magnesio stearas, silice colloidalis anhydrica pro compresso. - iperfosfatemia in pazienti adulti con insufficienza renale cronica in dialisi (emodialisi, dialisi peritoneale) - synthetika
tavneos 10 mg capsule rigide
vifor fresenius medical care renal pharma ltd. - avacopanum - capsule rigide - avacopanum 10 mg, macrogolglyceroli hydroxystearas 245 mg, macrogolum 4000, kapselhülle: e 172 (rubrum), e 172 (flavum), e 171, gelatina, polysorbatum 80, drucktinte: e 172 (nigrum), pro capsula. - behandlung erwachsener patienten mit schwerer aktiver vaskulitis (granulomatose mit polyangiitis (gpa) oder mikroskopischer polyangiitis (mpa)) - synthetika
veltassa
vifor fresenius medical care renal pharma france - patiromer sorbitex calcio - iperkaliemia - farmaci per il trattamento di iperkaliemia ed iperfosfatemia - veltassa è indicato per il trattamento dell'iperkaliemia negli adulti.
kapruvia
vifor fresenius medical care renal pharma france - difelikefalin - pruritus - tutti gli altri prodotti terapeutici - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.
tavneos
vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunosoppressori - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).
rayaldee 30 µg weichkapseln retardiert
vifor fresenius medical care renal pharma ltd. - calcifediolum - weichkapseln retardiert - calcifediolum 30 µg ut calcifediolum monohydricum, paraffinum solidum, paraffinum liquidum, hypromellosum, glyceroli monostearas 40-55, macrogolglyceridorum laurates, ethanolum anhydricum 3.944 mg, e 321, kapselhülle: amylum hydroxypropylum, carrageenanum, sorbitolum liquidum partim deshydricum corresp. sorbitolum 18 mg, dinatrii phosphas corresp. natrium 0.3 mg, titanii dioxidum, e 133, aqua purificata pro capsula. - rayaldee ist zur behandlung von sekundärem hyperparathyreoidismus (shpt) bei erwachsenen mit chronischer niereninsuffizienz (ckd) im stadium 3 oder 4 und 25- hydroxyvitamin-d-serumwerten <30 ng/ml indiziert. - synthetika
veltassa 8.4 g polvere per sospensione orale
vifor fresenius medical care renal pharma ltd. - patiromerum - polvere per sospensione orale - suspension: patiromerum calcicum sorbitolum 16.8 g corresp. patiromerum 8.4 g et sorbitolum 3.765 g, xanthani gummi, ad pulverem. - iperkaliemia - synthetika
veltassa 16.8 g polvere per sospensione orale
vifor fresenius medical care renal pharma ltd. - patiromerum - polvere per sospensione orale - patiromerum calcicum sorbitolum 33.6 g corresp. patiromerum 16.8 g et sorbitolum 7.53 g, xanthani gummi, ad pulverem. - iperkaliemia - synthetika
rayaldee
vifor fresenius medical care renal pharma france - calcifediolo - calcifediolo